Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Fate Therapeutics (NQ: FATE ) 3.840 +0.070 (+1.86%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,176,015 Open 3.830 Bid (Size) 3.810 (2) Ask (Size) 3.930 (70) Prev. Close 3.770 Today's Range 3.710 - 3.955 52wk Range 1.630 - 8.830 Shares Outstanding 98,384,456 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 13, 2024 FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates August 13, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Performance YTD +4.07% +4.07% 1 Month -25.87% -25.87% 3 Month +9.09% +9.09% 6 Month -44.83% -44.83% 1 Year +50.00% +50.00% More News Read More Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) August 02, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors July 31, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts June 17, 2024 Via Benzinga Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? July 21, 2024 Via The Motley Fool Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session July 16, 2024 Via Benzinga UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday July 16, 2024 Via Benzinga Forecasting The Future: 8 Analyst Projections For Fate Therapeutics May 06, 2024 Via Benzinga Where Fate Therapeutics Stands With Analysts April 11, 2024 Via Benzinga Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) July 02, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday June 17, 2024 Via Benzinga Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) June 04, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference May 29, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday May 16, 2024 Via Benzinga FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates May 09, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program May 09, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates May 06, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting May 03, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting April 22, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session April 10, 2024 Via Benzinga Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) April 02, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement March 19, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.